These combined results may imply that, by evaluating the expression level of Nrf2 in the nucleus of gastric cancer cells, it might be possible to predict the best candidates who can benefit from receiving not only adjuvant chemotherapy but also neoadjuvant chemotherapy. Here, NFE2L2 is linked to gastric cancer.